Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.860 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,303
Open 3.860
Bid (Size) 3.860 (100)
Ask (Size) 3.980 (100)
Prev. Close 3.860
Today's Range 3.860 - 3.860
52wk Range 2.900 - 7.730
Shares Outstanding 95,598,665
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial. 
Via Stocktwits
News headline image
Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗
Altimmune (ALT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+10.0%
+10.0%
1 Month
-17.7%
-17.7%
3 Month
-30.1%
-30.1%
6 Month
+2.1%
+2.1%
1 Year
-29.2%
-29.2%

More News

Read More
Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗
Via Chartmill
Topics Earnings
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
Via The Motley Fool
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Government Lawsuit
News headline image
ALT Stock Rallies 4% — What Does Retail Think? ↗
Via Stocktwits
News headline image
Why Are Investors Looking At Altimmune Stock? ↗
Via Benzinga
News headline image
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗
Via Stocktwits
News headline image
Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗
Via Stocktwits
News headline image
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗
Via Stocktwits
News headline image
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?
Yes, Altimmune, Inc. - Common Stock is publicly traded.
What exchange does Altimmune, Inc. - Common Stock trade on?
Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Altimmune, Inc. - Common Stock?
The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market
What is the current price of Altimmune, Inc. - Common Stock?
The current price of Altimmune, Inc. - Common Stock is 3.860
When was Altimmune, Inc. - Common Stock last traded?
The last trade of Altimmune, Inc. - Common Stock was at 03/10/26 04:00 PM ET
What is the market capitalization of Altimmune, Inc. - Common Stock?
The market capitalization of Altimmune, Inc. - Common Stock is 369.01M
How many shares of Altimmune, Inc. - Common Stock are outstanding?
Altimmune, Inc. - Common Stock has 369M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.